1. Pink Sheet
  2. >>Market Access

US FDA Wants To Help Sponsors Generate Evidence CMS Needs, But Won't Be An Intermediary

 
• By Derrick Gingery

FDA-CMS communications are expected to evolve as both agencies look to improve their relationship.

collaboration
There is no completed program yet on FDA-CMS communications, FDA chief of staff Julia Tierney said. • Source: Shutterstock

The US Food and Drug Administration is interested in helping ensure sponsors collect the data needed by it and the Centers for Medicare and Medicaid Services by the time they submit marketing applications – part of an evolving effort between the agencies to improve their communications and aid sponsors.

FDA Chief of Staff Julia Tierney said 17 October that FDA staff are working hard to ensure all the necessary...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

Recent And Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK-Wide Strategy Needed To Move Clinical Trial Diversity Plans To Next Stage

 
• By Vibha Sharma

The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.

Blenrep’s Comeback Continues As England Becomes First To Fund Drug

 
• By Eliza Slawther

Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.